Introduction: In this study, we explored the potential of plasma growth hormone (GH) as a prognostic biomarker in patients with advanced HCC treated with durvalumab plus tremelimumab (D+T).
Methods: In this study, we included 16 patients with advanced HCC who received D+T at MD Anderson Cancer Center between 2022 and 2023 and had plasma GH measurements recorded before treatment. Plasma GH levels were measured from prospectively collected blood samples and were correlated with progression-free survival (PFS) and overall survival (OS). The cutoff for normal GH levels in women and men was defined as ≤ 3.7 μg/L and ≤ 0.9 μg/L, respectively. The Kaplan–Meier method was employed to compute the median OS and PFS, while the Log rank test was applied to compare the survival outcomes between the GH-high and GH-low groups.
Results: Sixteen patients were included in this analysis, two female and fourteen male, with a median age of 65.5 years. At the time of the analysis, the 6-month OS rate was 100% among GH-low patients (6 patients) and 30% among GH-high patients (10 patients). OS was significantly longer in GH-low patients (not evaluable) compared to GH-high patients (3.94 months) (p = 0.030). PFS was also significantly longer in GH-low patients (not evaluable) compared to the GH-high patients (1.87 months) (p = 0.036).
Conclusion: Plasma GH is a prognostic biomarker in patients with advanced HCC treated with D+T. Given the relatively small patient cohort size, this finding should be further validated in larger randomized clinical trials in advanced HCC patients.

Keywords: hepatocellular carcinoma, growth hormone, durvalumab, tremelimumab, overall survival, progression-free survival


中文翻译：

---

血浆生长激素作为晚期肝细胞癌患者 Durvalumab 和 Tremelimumab 的预后生物标志物

简介：在这项研究中，我们探讨了血浆生长激素 (GH) 作为接受 durvalumab 加 tremelimumab (D+T) 治疗的晚期 HCC 患者的预后生物标志物的潜力。
方法：在这项研究中，我们纳入了 16 名晚期 HCC 患者，他们于 2022 年至 2023 年间在 MD 安德森癌症中心接受了 D+T，并在治疗前记录了血浆 GH 测量值。血浆 GH 水平通过前瞻性采集的血液样本进行测量，并与无进展生存期 (PFS) 和总生存期 (OS) 相关。女性和男性正常 GH 水平的临界值分别定义为 ≤ 3.7 μg/L 和 ≤ 0.9 μg/L。采用 Kaplan-Meier 方法计算中位 OS 和 PFS，同时采用对数秩检验比较 GH 高组和 GH 低组之间的生存结果。
结果：本次分析纳入 16 名患者，其中 2 名女性，14 名男性，中位年龄 65.5 岁。在分析时，GH 低患者（6 名患者）的 6 个月 OS 率为 100%，GH 高患者（10 名患者）的 6 个月 OS 率为 30%。与 GH 高患者（3.94 个月）相比，GH 低患者的 OS 显着更长（无法评估）（p = 0.030）。与 GH 高患者（1.87 个月）相比，GH 低患者（不可评估）的 PFS 也显着更长（p = 0.036）。
结论：血浆 GH 是接受 D+T 治疗的晚期 HCC 患者的预后生物标志物。鉴于患者队列规模相对较小，这一发现应在晚期 HCC 患者的更大型随机临床试验中得到进一步验证。

关键词:肝细胞癌, 生长激素, durvalumab, tremelimumab, 总生存期, 无进展生存期